InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to the company’s Board of Directors as it advances commercialization efforts for its glycoproteomic diagnostic solutions.
The company said the additions come during a key phase of growth as it focuses on bringing glycoproteomics into clinical practice to support more informed clinical decision-making across complex diseases. InterVenn is developing glycoproteomic diagnostic solutions designed to uncover biological signals that traditional genomics and proteomics approaches may miss.
Ford brings more than 30 years of experience across the genomics, pharmaceutical, and biotechnology industries. He currently serves as CEO of Karius and previously held the role of chief operating officer at Myriad Genetics, where he helped launch and scale business units spanning women’s health, oncology, urology, and prenatal screening. He has also held leadership positions at Novartis, Sanofi, Nektar Therapeutics, and Pfizer. In addition, Ford is a founding board member of BioUtah.
Levine brings extensive experience in finance and corporate strategy within the biotechnology and diagnostics industries. He currently serves as CEO of Prenostics and most recently served as CEO and board chair of SmartHealth Diagnostics, where he oversaw digital imaging instrumentation development and laboratory expansion under CLIA/CAP accreditation. Levine previously served as chief financial officer of Oncocyte, leading ten capital raises and three strategic acquisitions. He also serves as an independent director of Codetta BioSciences, chair of the board at Clarus Dx, and previously served as board chair of ImmunoPrecise Antibodies. Levine founded Enable Capital Management in 2000 to provide growth capital to technology and life sciences companies.
InterVenn said the combined expertise of Ford and Levine in diagnostics commercialization, operational scaling, and financial strategy will support the company’s next stage of growth in precision medicine.
KEY QUOTES:
“We are excited to welcome Alec and Mitch to InterVenn’s Board of Directors at a pivotal moment for the company. Their combined expertise in diagnostics commercialization, operational scaling, and life sciences financial strategy will help accelerate our mission to bring glycoproteomics into clinical practice and unlock a new frontier in precision medicine.”
Andrew Quong, Ph.D., Chief Executive Officer, InterVenn Biosciences
